Abstract:A successful treatment of AIDS world-wide is severely hindered by the HIV virus' drug resistance capability resulting from complicated mutation patterns of viral proteins. Such a system of mutations enables the virus to survive and reproduce despite the presence of various antiretroviral drugs by disrupting their binding capability. Although these interacting mutation patterns are extremely difficult to efficiently uncover and interpret, they contribute valuable information to personalized therapeutic regimen design. The use of Bayesian statistical modeling provides an unprecedented opportunity in the field of anti-HIV therapy to understand detailed interaction structures of drug resistant mutations. Multiple Bayesian models equipped with Markov Chain Monte Carlo (MCMC) methods have been recently proposed in this field (Zhang et al. in PNAS 107: 1321, 2010 [1]; Zhang et al. in J Proteome Sci Comput Biol 1: 2, 2012 [2]; Svicher et al. in Antiviral Res 93(1): 86-93, 2012 [3]; Svicher et al. in Antiviral Therapy 16(7): 1035-1045, 2011 [4]; Svicher et al. in Antiviral Ther 16(4): A14-A14, 2011 [5]; Svicher et al. in Antiviral Ther 16(4): A85-A85, 2011 [6]; Alteri et al. in Signature mutations in V3 and bridging sheet domain of HIV-1 gp120 HIV-1 are specifically associated with dual tropism and modulate the interaction with CCR5 N-Terminus, 2011 [7]). Probabilistically modeling mutations in the HIV-1 protease or reverse transcriptase (RT) isolated from drug-treated patients provides a powerful statistical procedure that first detects mutation combinations associated with single or multiple-drug resistance, and then infers detailed dependence structures among the interacting mutations in viral proteins (Zhang et al. in PNAS 107: 1321, 2010 [1]; Zhang et al. in J Proteome Sci Comput Biol 1: 2, 2012 [2]). Combined with molecular dynamics simulations and free energy calculations, Bayesian analysis predictions help to uncover genetic and structural mechanisms in the HIV treatment resistance. Results obtained with such stochastic methods pave the way not only for optimization of the use for existing HIV drugs, but also for the development of the new more efficient antiretroviral medicines. In this chapter we survey current challenges in the bioinformatics of anti-HIV therapy, and outline how recently emerged Bayesian methods can help with the clinical management of HIV-1 infection. We will provide a rigorous review of the Bayesian variable partition model and the recursive model selection procedure based on probability theory and mathematical data analysis techniques while highlighting real applications in HIV and HBV studies including HIV drug resistance (Zhang et al. in PNAS 107: 1321, 2010 [1]), cross-resistance (Zhang et al. in J Proteome Sci Comput Biol 1: 2, 2012 [2]), HIV coreceptor usage (Svicher et al. in Antiviral Therapy 16(7): 1035-1045, 2011 [4]; Svicher et al. in Antiviral Ther 16(4): A14-A14, 2011 [5]; Alteri et al. in Signature mutations in V3 and bridging sheet domain of HIV-1 gp120 HIV-1 are specifically associated with dual tropism and modulate the interaction with CCR5 N-Terminus, 2011 [7]), and occult HBV infection (Svicher et al. in Antiviral Res 93(1): 86-93, 2012 [3]; Svicher et al. in Antiviral Ther 16(4): A85-A85, 2011 [6]).

Dynamic multidrug therapies for HIV: A control theoretic approach

Transmission dynamics and optimal control strategies in a multi-pathways delayed HIV infection model with multi-drug therapy

Evolutionary Game Theoretic Strategy for Optimal Drug Delivery to Influence Selection Pressure in Treatment of HIV-1

A New Mathematical Model for Assessing Therapeutic Strategies for HIV Infection

Sliding mode dynamics and optimal control for HIV model

Free Final-Time Optimal Control for HIV Viral Dynamics

Piecewise virus-immune dynamic model with HIV-1 RNA-guided therapy

Optimal Control Control Of Drug Therapy: Melding Pharmacokinetics With Viral Dynamics

VIRUS DYNAMICS MODELS SUBJECTED TO A HYBRID ON-OFF CONTROL

Anti-viral drug treatment along with immune activator IL-2: a control-based mathematical approach for HIV infection

Model-free based control of a HIV/AIDS prevention model

Bayesian analysis of complex interacting mutations in HIV drug resistance and cross-resistance.

Piecewise HIV Virus Dynamic Model with CD4(+) T Cell Count-Guided Therapy: I.

Modeling long-term longitudinal HIV dynamics with application to an AIDS clinical study

A Piecewise Model of Virus-Immune System with Effector Cell-Guided Therapy

Mathematical modelling of the within-host HIV quasispecies dynamics in response to antiviral treatment

Conflict and Accord of Optimal Treatment Strategies for HIV Infection Within and Between Hosts.

Mathematical modeling of escape of HIV from cytotoxic T lymphocyte responses

Early Viral Dynamics Predict HIV Post-Treatment Control After Analytic Treatment Interruption

A comprehensive stochastic computational model of HIV infection from DNA integration to viral burst

Optimal Control Strategies and Sensitivity Analysis of an HIV/AIDS-Resistant Model with Behavior Change